natgillin/translations-raw huggingface dataset:
For treatment of high blood pressure, the usual dose of Pritor for most patients is one 40 mg tablet once a day to control blood pressure over the 24 hour period. 
Za terapiju povišenog krvnog tlaka uobičajena doza Pritora za većinu bolesnika je jedna tableta od 40 mg jedanput na dan za kontrolu krvnog tlaka tijekom 24 sata.
Pritor 20 mg tablets Pack sizes: Blister with 14, 28, 30, 56, 90 or 98 tablets. 
Pritor 20 mg tablete Veličine pakiranja: Blister s 14, 28, 30, 56, 90 ili 98 tableta.
Pritor may also be used in combination with diuretics ('water tablets') such as hydrochlorothiazide which has been shown to have an additive blood pressure lowering effect with Pritor. 
Pritor se također može primjenjivati u kombinaciji s diureticima (tablete za mokrenje), kao što je hidroklorotiazid za koji se pokazalo da ima dodatan učinak snižavanja krvnog tlaka s Pritorom.
• manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or 
• manifestnom aterotrombotskom kardiovaskularnom bolešću (anamneza koronarne bolesti srca,
If concomitant use is indicated because of documented hypokalaemia, they should be used with caution and with frequent monitoring of serum potassium. 
Ako je indicirana istodobna primjena zbog zabilježene hipokalijemije, primjenjuje ih se oprezno i uz učestalo praćenje kalija u serumu.
In addition, there was a significantly higher incidence of hyperkalaemia, renal failure, hypotension and syncope in the combination arm. 
Nadalje, u skupini koja je primala kombinaciju postojala je znatno veća incidencija hiperkalijemije, zatajenja bubrega, hipotenzije i sinkope.
Pritor 20 mg tablets 3 years 
Pritor 20 mg tablete 3 godine
Pritor is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section). 
Pritor se ne preporučuje u ranoj trudnoći i ne smije se uzimati ako ste trudni dulje od 3 mjeseca jer može izazvati teška oštećenja Vašeg djeteta ako se primjenjuje u ovom stadiju (vidjeti dio o trudnoći).
No statistically significant difference in the incidence of the primary composite endpoint (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for congestive heart failure) was found [15.7 % in the telmisartan and 17.0 % in the placebo groups with a hazard ratio of 0.92 (95 % CI 0.81 - 1.05, p = 0.22)]. 
Nije pronađena statistički značajna razlika u incidenciji primarnog složenog ishoda (kardiovaskularna smrt, nefatalni infarkt miokarda, nefatalni moždani udar ili hospitalizacija zbog kongestivnog zatajenja srca) [15,7 % u skupini na telmisartanu i 17,0 % u skupini na placebu s omjerom rizika od 0,92 (95 % CI 0,81 - 1,05, p = 0,22)].
White round tablets of 2.5 mm engraved with the code number '50H' on one side and the company logo on the other side. 
Bijele, okrugle tablete od 2,5 mm s utisnutom oznakom „50H“ na jednoj strani i logom tvrtke na drugoj strani.
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS Blister of 7 tablets 
PODACI KOJE MORA NAJMANJE SADRŽAVATI BLISTER ILI STRIP Blister od 7 tableta
Furthermore, low blood pressure may be aggravated by alcohol, barbiturates, narcotics or antidepressants. 
Nadalje, niski krvni tlak može biti pogoršan uzimanjem alkohola, barbiturata, narkotika ili antidepresiva, što se može primijetiti u obliku omaglice prilikom ustajanja.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 11 December 1998 
DATUM PRVOG ODOBRENJA / DATUM OBNOVE ODOBRENJA
Pritor 40 mg and 80 mg tablets 4 years 
Pritor 40 mg i 80 mg tablete 4 godine
: for further descriptions, please see sub-section “Description of selected adverse reactions” Description of selected adverse reactions 
1, 2, 3, 4: za daljnje opise, molimo vidjeti pod “Opis odabranih nuspojava”.
Pritor is available in blister packs containing 14, 28, 30, 56, 90 or 98 tablets. 
Pritor je dostupan u blister pakiranjima od 14, 28, 30, 56, 90 ili 98 tableta.
Pritor is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy. 
Pritor se ne preporučuje u ranoj trudnoći te se ne smije uzimati ako ste trudni dulje od 3 mjeseca jer može izazvati teška oštećenja djeteta ako se primjenjuje nakon trećeg mjeseca trudnoće.
If your liver is not working properly, the usual dose should not exceed 40 mg once daily. 
U bolesnika s oštećenom jetrom, uobičajena doza ne smije prelaziti 40 mg jedanput na dan.
Each 80 mg tablet contains 338 mg sorbitol (E420). 
Svaka tableta od 80 mg sadrži 338 mg sorbitola (E420).
Each 40 mg tablet contains 169 mg sorbitol (E420). 
Svaka tableta od 40 mg sadrži 169 mg sorbitola (E420).
Pritor 80 mg tablets White oblong tablets of 4.6 mm engraved with the code number '52H' on one side. 
Pritor 80 mg tablete Bijele, duguljaste tablete od 4,6 mm s utisnutom oznakom „52H“ na jednoj strani.
Pritor 40 mg tablets White oblong tablets of 3.8 mm engraved with the code number '51H' on one side. 
Pritor 40 mg tablete Bijele, duguljaste tablete od 3,8 mm s utisnutom oznakom „51H“ na jednoj strani.
Pack sizes: Blister with 14, 28, 30, 56, 90, 98 or 280 tablets or perforated unit dose blisters with 28 x 1 tablets. 
Veličine pakiranja: blister s 14, 28, 30, 56, 98 ili 280 tableta ili perforirani blisteri djeljivi na jedinične doze s 28 x 1 tableta.
• if you are taking any of the following medicines used to treat high blood pressure: - an ACE-inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetes-related kidney problems. 
• ako uzimate bilo koji od sljedećih lijekova navedenih u nastavku, koji se koriste za liječenje visokog krvnog tlaka: - ACE-inhibitor (primjerice enalapril, lizinopril, ramipril), osobito ako imate bubrežne tegobe povezane sa šećernom bolešću. - aliskiren.
Pruritus, hyperhidrosis, , rash Angioedema (also with fatal outcome), eczema, erythema, urticaria, drug eruption, toxic skin eruption 
Angioedem (također sa smrtnim ishodom), ekcem, eritem, urtikarija, osip od lijeka, toksični osip kože
(It is also better to avoid Pritor in early pregnancy see pregnancy section.) 
• Ako ste dulje od 3 mjeseca trudni (također je bolje izbjegavati Pritor u ranoj trudnoći - vidjeti dio o trudnoći).
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER Bayer AG 
11. NAZIV I ADRESA NOSITELJA ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET Bayer AG
When pregnancy is diagnosed, treatment with angiotensin II receptor antagonists should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 
Kada se utvrdi trudnoća, liječenje antagonistima receptora angiotenzina II mora se trenutno prekinuti te, ako je potrebno, započeti s primjenom drugog lijeka (vidjeti dijelove 4.3 i 4.6).
Cases of interstitial lung disease have been reported from post-marketing experience in temporal association with the intake of telmisartan. 
Nakon stavljanja lijeka u promet zabilježena je vremenska povezanost slučajeva intersticijske bolesti pluća s unosom telmisartana.
You should store your medicine in the original package in order to protect the tablets from moisture. 
Čuvajte lijek u originalnom pakiranju radi zaštite tableta od vlage.
In the "Prevention Regimen For Effectively avoiding Second Strokes" (PRoFESS) trial in patients 50 years and older, who recently experienced stroke, an increased incidence of sepsis was noted for telmisartan compared with placebo, 0.70 % vs. 0.49 % [RR 1.43 (95 % confidence interval 1.002.06)]; the incidence of fatal sepsis cases was increased for patients taking telmisartan (0.33 %) vs. patients taking placebo (0.16 %) [RR 2.07 (95 % confidence interval 1.14 - 3.76)]. 
“Prevention Regimen For Effectively avoiding Second Strokes”) u bolesnika u dobi od 50 godina i starijih, koji su nedavno imali moždani udar, zabilježena je povećana incidencija sepse za telmisartan u usporedbi s placebom, 0,70 % u odnosu na 0,49 % RR 1,43 (95 % interval pouzdanosti 1,00 - 2,06).
Medicinal products or therapeutic classes of medicinal products that may provoke hyperkalaemia are salt substitutes containing potassium, potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, non steroidal anti-inflammatory medicinal products (NSAIDs, including selective COX-2 inhibitors), heparin, immunosuppressives (cyclosporin or tacrolimus), and trimethoprim. 
Lijekovi ili terapijske klase lijekova koji mogu izazvati hiperkalijemiju su nadomjesci soli koje sadrže kalij, diuretici koji štede kalij, ACE-inhibitori, antagonisti receptora angiotenzina II, nesteroidni antiinflamatorni lijekovi (NSAIL, uključujući selektivne COX-2 inhibitore), heparin, imunosupresivi (ciklosporin ili takrolimus) i trimetoprim.
Pritor is available in blister packs containing 14, 28, 30, 56, 90, 98 or 280 tablets, or unit dose blister packs containing 28 x 1 tablets. 
Pritor je dostupan u blister pakiranjima od 14, 28, 30, 56, 90, 98 ili 280 tableta i blisterima djeljivim na jedinične doze s 28 x 1 tableta.
INFORMATION IN BRAILLE Pritor 40 mg 
16. PODACI NA BRAILLEOVOM PISMU Pritor 40 mg
INFORMATION IN BRAILLE Pritor 20 mg 
16. PODACI NA BRAILLEOVOM PISMU Pritor 20 mg
• Medicines that may increase blood potassium levels such as salt substitutes containing potassium, potassium-sparing diuretics (certain 'water tablets'), ACE inhibitors, angiotensin II receptor antagonists, NSAIDs (non steroidal anti-inflammatory medicines, e.g. aspirin or ibuprofen), heparin, immunosuppressives (e.g. cyclosporin or tacrolimus), and the antibiotic trimethoprim. 
• Lijekovi koji mogu povisiti razine kalija u krvi kao što su nadomjesci soli koje sadrže kalij, diuretici koji štede kalij (određene tablete za mokrenje), ACE-inhibitori, antagonisti receptora angiotenzina II, NSAIL (nesteroidni protuupalni lijekovi, npr. aspirin ili ibuprofen), heparin, imunosupresivi (npr. ciklosporin ili takrolimus) te antibiotik trimetoprim.
• Diabetes. 
• Šećerna bolest.
INFORMATION IN BRAILLE Pritor 80 mg 
16. PODACI NA BRAILLEOVOM PISMU Pritor 80 mg
Slovenská republika Bayer, spol. 
Slovenská republika Bayer, spol. s r.o.
What Pritor looks like and contents of the pack Pritor 40 mg tablets are white, oblong-shaped and engraved with the code '51H' on one. 
Kako Pritor izgleda i sadržaj pakiranja Pritor 40 mg tablete su bijele, duguljastog oblika, s utisnutom oznakom „51H“ na jednoj strani.
Pritor 40 mg and 80 mg tablets 
Pritor 40 mg i 80 mg tablete
Pritor 40 mg tablets 
Pritor 40 mg tablete
Sepsis* (often called "blood poisoning " is a severe infection with whole-body inflammatory response which can lead to death), increase in certain white blood cells (eosinophilia), low platelet count (thrombocytopenia), severe allergic reaction (anaphylactic reaction), allergic reaction (e.g. rash, itching, difficulty breathing, wheezing, swelling of the face or low blood pressure), low blood sugar levels (in diabetic patients), feeling anxious, somnolence, impaired vision, fast heart beat (tachycardia), dry mouth, upset stomach, taste disturbance (dysgeusia), abnormal liver function (Japanese patients are more likely to experience this side effect), rapid swelling of the skin and mucosa which can also lead to death (angioedema also with fatal outcome), eczema (a skin disorder), redness of skin, hives (urticaria), severe drug rash, joint pain (arthralgia), pain in extremity, tendon pain, flu-like-illness, decreased haemoglobin (a blood protein), increased levels of uric acid, increased hepatic enzymes or creatine phosphokinase in the blood. 
Sepsa* (često nazvana „trovanje krvi“ je teška infekcija s upalnim odgovorom cijelog organizma što može dovesti do smrtnog ishoda), povećanje određenih bijelih krvnih stanica (eozinofilija), nizak broj krvnih pločica (trombocitopenija), teška alergijska reakcija (anafilaktička reakcija), alergijska reakcija (npr. osip, svrbež, otežano disanje, piskanje, oticanje lica ili nizak krvni tlak), niske razine šećera u krvi (u bolesnika sa šećernom bolesti), osjećaj tjeskobe, izrazita pospanost, oštećen vid, ubrzani otkucaji srca (tahikardija), suhoća usta, nadražaj želuca, poremećaj osjeta okusa (disgeuzija), abnormalna funkcija jetre (vjerojatnost da će iskusiti ovu nuspojavu, veća je za bolesnike iz Japana), brzo oticanje kože i sluznice koji mogu dovesti do smrtnog ishoda (angioedem također sa smrtnim ishodom), ekcem (poremećaj kože), crvenilo kože, koprivnjača (urtikarija), težak osip od lijeka, bol u zglobovima (artralgija), bol u udovima, bol tetiva, simptomi nalik gripi, snižen hemoglobin (krvni protein), povišena razina mokraćne kiseline, povišeni jetreni enzimi ili kreatin fosfokinaza u krvi.
Urinary tract infections, upper respiratory tract infections (e.g. sore throat, inflamed sinuses, common cold), deficiency in red blood cells (anaemia), high potassium levels, difficulty falling asleep, feeling sad (depression), fainting (syncope), feeling of spinning (vertigo), slow heart rate (bradycardia), low blood pressure (hypotension) in users treated for high blood pressure, dizziness on standing up (orthostatic hypotension), shortness of breath, cough, abdominal pain, diarrhoea, discomfort in the abdomen, bloating, vomiting, itching, increased sweating, drug rash, back pain, muscle cramps, muscle pain (myalgia), kidney impairment including acute kidney failure, pain in the chest, feeling of weakness, and increased level of creatinine in the blood. 
Infekcije mokraćnih puteva, infekcije gornjih dišnih puteva (npr. grlobolja, upala sinusa, česta prehlada), nedostatak crvenih krvnih stanica (anemija), visoke razine kalija, otežano uspavljivanje, osjećaj tuge (depresija), nesvjestica (sinkopa), osjećaj vrtnje (vrtoglavica), usporen rad srca (bradikardija), nizak krvni tlak (hipotenzija) u korisnika liječenih zbog visokog krvnog tlaka, omaglica pri ustajanju (ortostatska hipotenzija), nedostatak zraka, kašalj, bol u trbuhu, proljev, nelagoda u trbuhu, nadutost, povraćanje, svrbež, pojačano znojenje, osip na lijek, bol u leđima, grčevi mišića, bol mišića (mialgija), poremećaj rada bubrega uključujući akutno zatajenje bubrega, bol u prsima, osjećaj slabosti i povišena razina kreatinina u krvi.
What Pritor looks like and contents of the pack Pritor 80 mg tablets are white, oblong-shaped and engraved with the code '52H' on one. 
Kako Pritor izgleda i sadržaj pakiranja Pritor 80 mg tablete su bijele, duguljastog oblika, s utisnutom oznakom „52H“ na jednoj strani.
Sepsis* (often called "blood poisoning", is a severe infection with whole-body inflammatory response), rapid swelling of the skin and mucosa (angioedema); these side effects are rare may affect up to 1 in 1,000 people) but are extremely serious and patients should stop taking the medicine and see their doctor immediately. 
Sepsa* (često nazvana „trovanje krvi“ je teška infekcija s upalnim odgovorom cijelog organizma), brzo oticanje kože i sluznice (angioedem).
Pritor 20 mg tablets 
Pritor 20 mg tablete
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS Any non 7 count blister 
PODACI KOJE MORA NAJMANJE SADRŽAVATI BLISTER ILI STRIP Svaki blister koji ne sadrži 7 tableta
Therefore, in these patients an appropriate blood glucose monitoring should be considered; a dose adjustment of insulin or antidiabetics may be required, when indicated. 
Stoga, u ovih bolesnika treba adekvatno kontrolirati glukozu u krvi.
Marketing Authorisation Holder Bayer AG 
NOSITELJ ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET Bayer AG
Hepatic function abnormal/liver disorder Skin and subcutaneous tissue disorders Uncommon: Rare: 
Poremećaji kože i potkožnog tkiva Manje često: Rijetko:
Pritor 80 mg tablets 
Pritor 80 mg tablete
The main risk factors for hyperkalaemia to be considered are: - Diabetes mellitus, renal impairment, age (>70 years) - Combination with one or more other medicinal products that affect the renin-angiotensinaldosterone system and/or potassium supplements. 
Glavni faktori rizika za hiperkalijemiju koji se moraju razmotriti su: - Dijabetes melitus, poremećaj funkcije bubrega, dob (>70 godina).
METHOD AND ROUTE(S) OF ADMINISTRATION Oral use. 
5. NAČIN I PUT(EVI) PRIMJENE LIJEKA Za primjenu kroz usta.
Package leaflet: Information for the user Pritor 40 mg tablets Telmisartan 
Uputa o lijeku: Informacije za korisnika Pritor 40 mg tablete telmisartan
EU/1/98/089/011 (14 tablets) EU/1/98/089/012 (28 tablets) EU/1/98/089/020 (30 tablets) EU/1/98/089/013 (56 tablets) EU/1/98/089/019 (90 tablets) EU/1/98/089/014 (98 tablets) 
EU/1/98/089/011 (14 tableta) EU/1/98/089/012 (28 tableta) EU/1/98/089/020 (30 tableta) EU/1/98/089/013 (56 tableta) EU/1/98/089/019 (90 tableta) EU/1/98/089/014 (98 tableta)
Back pain (e.g. sciatica), muscle spasms, myalgia, Arthralgia, pain in extremity, tendon pain (tendinitis like symptoms) 
Bol u leđima (npr. išijas), grčevi mišića, mijalgija, Artralgija, bol u ekstremitetima, bol tetiva (simptomi poput tendinitisa) Poremećaji bubrega i mokraćnog sustava Manje često:
Package leaflet: Information for the user Pritor 80 mg tablets Telmisartan 
Uputa o lijeku: Informacije za korisnika Pritor 80 mg tablete telmisartan
Package leaflet: Information for the user Pritor 20 mg tablets Telmisartan 
Uputa o lijeku: Informacije za korisnika Pritor 20 mg tablete telmisartan
NAME OF THE MEDICINAL PRODUCT Pritor 20 mg tablets 
NAZIV LIJEKA Pritor 20 mg tablete
The most prominent manifestations of telmisartan overdose were hypotension and tachycardia; bradycardia, dizziness, increase in serum creatinine, and acute renal failure have also been reported. 
Najizraženije manifestacije predoziranja telmisartanom bile su hipotenzija i tahikardija.
Each 20 mg tablet contains 84 mg sorbitol (E420). 
Pomoćne tvari s poznatim učinkom Svaka tableta od 20 mg sadrži 84 mg sorbitola (E420).
NAME OF THE MEDICINAL PRODUCT Pritor 80 mg tablets telmisartan 
NAZIV LIJEKA Pritor 80 mg tablete telmisartan
NAME OF THE MEDICINAL PRODUCT Pritor 40 mg tablets telmisartan 
NAZIV LIJEKA Pritor 40 mg tablete telmisartan
NAME OF THE MEDICINAL PRODUCT Pritor 20 mg tablets telmisartan 
NAZIV LIJEKA Pritor 20 mg tablete telmisartan
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 20 mg telmisartan. 
2. NAVOĐENJE DJELATNE(IH) TVARI Svaka tableta sadrži 20 mg telmisartana.
What Pritor looks like and contents of the pack Pritor 20 mg tablets are white, round and engraved with the code number '50H' on one side and the company logo on the other side. 
Pritor 20 mg tablete su bijele, okrugle s utisnutom oznakom „50H“ na jednoj i logom tvrtke na drugoj strani.
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 80 mg telmisartan. 
2. NAVOĐENJE DJELATNE(IH) TVARI Svaka tableta sadrži 80 mg telmisartana.
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 40 mg telmisartan. 
2. NAVOĐENJE DJELATNE(IH) TVARI Svaka tableta sadrži 40 mg telmisartana.
EU/1/98/089/001 (14 tablets) EU/1/98/089/002 (28 tablets) EU/1/98/089/021 (30 tablets) EU/1/98/089/003 (56 tablets) EU/1/98/089/017 (90 tablets) EU/1/98/089/004 (98 tablets) EU/1/98/089/005 (280 tablets) EU/1/98/089/015 (28 x 1 tablets) 
EU/1/98/089/001 (14 tableta) EU/1/98/089/002 (28 tableta) EU/1/98/089/021 (30 tableta) EU/1/98/089/003 (56 tableta) EU/1/98/089/017 (90 tableta) EU/1/98/089/004 (98 tableta) EU/1/98/089/005 (280 tableta) EU/1/98/089/015 (28 x 1 tableta)
EU/1/98/089/006 (14 tablets) EU/1/98/089/007 (28 tablets) EU/1/98/089/022 (30 tablets) EU/1/98/089/008 (56 tablets) EU/1/98/089/018 (90 tablets) EU/1/98/089/009 (98 tablets) EU/1/98/089/010 (280 tablets) EU/1/98/089/016 (28 x 1 tablets) 
EU/1/98/089/006 (14 tableta) EU/1/98/089/007 (28 tableta) EU/1/98/089/022 (30 tableta) EU/1/98/089/008 (56 tableta) EU/1/98/089/018 (90 tableta) EU/1/98/089/009 (98 tableta) EU/1/98/089/010 (280 tableta) EU/1/98/089/016 (28 x 1 tableta)
Renal impairment including acute renal failure General disorders and administration site conditions Uncommon: Rare: 
Opći poremećaji i reakcije na mjestu primjene Manje često: Rijetko:
Ear and labyrinth disorders Uncommon: 
Poremećaj vida Poremećaji uha i labirinta Manje često:
Insuman should be given before meals. 
Insuman treba davati prije obroka.
The medicine can only be obtained with a prescription. 
Lijek se može dobiti samo na recept.
The pump must not be implanted in people who reside permanently at elevations above at elevations above 2,439 metres (8000 feet). 
Pumpa se ne smije ugrađivati osobama koje imaju trajno prebivalište na visinama iznad 2 439 m (8 000 stopa).
The full EPAR for Insuman can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Cjelovito Europsko javno izvješće o ocjeni dokumentacije o lijeku (EPAR) može se naći na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Insuman may cause hypoglycaemia. 
Insuman može uzrokovati hipoglikemiju.
The European Commission granted a marketing authorisation valid throughout the European Union for Insuman on 21 February 1997. 
Europska komisija izdaje odobrenje za stavljanje u promet koje za Insuman vrijedi na prostoru Europske unije od 21. veljače 1997.
The Insuman range is comprised of: 
Raspon lijeka Insuman sastoji se od:
Other information about Insuman 
Druge informacije o Insumanu
The injection site is changed for each injection. 
Sa svakom injekcijom treba mijenjati mjesto injektiranja.
The patient's blood glucose should be tested regularly to find the lowest effective dose. 
Glukozu u bolesnikovoj krvi treba testirati redovito kako bi se otkrila najniža učinkovita doza.
By controlling the level of blood glucose, the symptoms and complications of diabetes are reduced. 
Kontrolom razine glukoze u krvi, smanjuju se simptomi i komplikacije dijabetesa.
Insuman must not be used in people who are hypersensitive (allergic) to human insulin or any of the other ingredients. 
Insuman ne smiju koristiti ljudi preosjetljivi (alergični) na humani inzulin ili na bilo koje druge sastojke.
Insuman human insulin 
Insuman humani inzulin
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Insuman. 
Objašnjava kako je Povjerenstvo za humane lijekove (CHMP) ocijenilo Insuman da bi postiglo mišljenje u korist davanja odobrenja za stavljanje u promet i preporučilo uvjete za njegovu primjenu.
What is the risk associated with Insuman? 
Koji su rizici povezani s Insumanom?
Insuman Rapid may also be given into a vein, but only in an intensive care unit or similar setting where the patient can be closely monitored. 
Insuman Rapid može se također dati u venu, ali samo u jedinicama intenzivne njege ili u sličnim ustanovama u kojima se bolesnika može pomno nadzirati.
This is a summary of the European public assessment report (EPAR) for Insuman. 
Ovo je sažetak Europskoga javnog izvješća o ocjeni dokumentacije lijeka (EPAR) za Insuman.
For more information about treatment with Insuman, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Više informacija o liječenju lijekom Insuman pročitajte u uputi o lijeku (također dio EPAR-a) ili se obratite svom liječniku ili ljekarniku.
• Insuman Comb, which is available in various combinations of fast- and intermediate-acting insulins. 
• Insuman Comb koji je dostupan u različitim kombinacijama brzih i srednjedjelujućih inzulina.
What is Insuman? 
Što je Insuman?
Why has Insuman been approved? 
Zašto je Insuman odobren?
It must also not be used in patients who are hypersensitive to titanium alloy, polysulfone or silicone material used in the components of the implanted pump. 
Također ga ne smiju koristiti bolesnici koji su preosjetljivi na leguru titana, polisulfon ili silikonski materijal koji se koristi u komponentama ugrađene pumpe.
Insuman is used in patients with diabetes (type 1 and 2) who need treatment with insulin. 
Insuman se koristi u bolesnika s dijabetesom (tip 1 i 2) koji trebaju liječenje inzulinom.